Brief: In8bio Presents Clinical Update From Ongoing Phase 1 Trial Of Inb-100 In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

IN8bio

28/03/2022 13:57

March 28 (Reuters) - IN8BIO, Inc.  INAB.O :
    * IN8BIO PRESENTS CLINICAL UPDATE FROM THE ONGOING PHASE 1
TRIAL
OF INB-100, AN ALLOGENEIC GAMMA-DELTA T CELL THERAPY IN LEUKEMIA
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
    * IN8BIO, INC. - ALL THREE PATIENTS WITH HIGH-RISK OR
RELAPSED
ACUTE-MYELOID LEUKEMIA (AML) DOSED TO-DATE WITH INB-100
DEMONSTRATED DURABLE REMISSIONS
    * IN8BIO, INC. - SAFETY PROFILE CONTINUES TO BE MANAGEABLE

Source text for Eikon:  ID:nGNXc2tK8B 
Further company coverage:  INAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))